The U.S. FDA announced that the District Court for the Middle District of Florida entered a consent decree that prohibits Hill Dermaceuticals, Inc., and Hill Labs, Inc. from introducing adulterated drugs into interstate commerce.
This Consent Decree describes numerous deviations from current good manufacturing practice (cGMP) for drugs documented during the FDA’s inspections of Hill. FDA further alleges that Hill has, on more than one occasion, submitted untrue statements in support of submissions to the FDA. These falsified submissions are evidence of persistent data integrity problems at Hill.
Read FDA’s Press Release. Go to: www.gmptrainingsystems.com/resources
Click on Timely Resource Articles
Serving 1951 clients since 1989
Upcoming Boot Camps
Click below for our 2011/2012 schedule
GMP Boot Camp – Fundamentals of GMP and QSR
Oct 19 – 20 Newark, NJ
Upcoming web seminars
Cost effective & Convenient – in your office or conference room
How to Conduct a Successful Supplier Audit: Protecting Your Supply Chain
Implementing FDA’s Guidance on a Quality Systems Approach to Pharmaceutical cGMP Regulations
Outsourcing in the Healthcare Industry: Avoiding the Perils and Pitfalls
How to Implement FDA’s New Guidance on Process Validation
ASTM E2500 Consensus Standard: An Overview of a New Approach to Validation
Proven Steps to Reducing Waste in Process Validation
Please forward this to others in your organization who may benefit.